Results for autoimmune diseases translation from English to Maltese

autoimmune disease
mard awtoimmuni

(autoimmune disease).
tiegħek stess (marda awtoimmuni).

these are used mainly in rheumatic and autoimmune diseases.
dawn jintużaw primarjament f’mard rewmatiku u awtoimmuni.

no studies have been performed in dogs with known autoimmune diseases.
ma sarux studji fi klieb magħrufa li għandhom mard autoimmune.

patients with autoimmune disease
pazjenti b’marda awtoimmuni

blys levels are elevated in patients with sle and other autoimmune diseases.
livelli ta’ blys huma ogħla f’pazjenti li għandhom sle u mard awtoimmuni ieħor.

ed term treatment with trudexa on the development of autoimmune diseases is unknown.
l- impatt tal- kura b ’ trudexa fit- tul fuq l- iżvilupp ta ’ mard awtoimmuni m’ huwiex magħruf.

no clinical data exist concerning the use of circadin in individuals with autoimmune diseases.
m’hemmx tagħrif disponnibli dwar l-użu ta’ circadin f’individwi b’mard awto-immun.

the impact of long- term treatment with humira on the development of autoimmune diseases is unknown.
l-impatt tal-kura b’ humira fit-tul fuq l-iżvilupp ta’ mard awtoimmuni m’huwiex magħruf.

there is also a potential risk of autoimmune disease.
hemm ukoll il-potenzjal ta' riskju ta' mard awtoimmuni.

autoimmune hepatitis; or history of autoimmune disease.
epatite awtoimmuni; jew jekk xi darba kien hemm mard awtoimmuni.

cases of progressive multifocal leukoencephalopathy with fatal outcome have been reported following use of mabthera for the treatment of autoimmune diseases.
wara l-użu ta’ mabthera għall-kura ta’ mard awtoimmuni kienu rrappurtati każijiet ta’ lewkoenċefalopatija multifokali progressiva (pml) b’riżultat fatali.

they can also be used in patients who need additional antibodies for the cure of certain inflammatory disorders (autoimmune diseases).
mediċini bħal kiovig jintużaw f' pazjenti li m’ għandhomx biżżejjed antikorpi fid- demm tagħhom u b' hekk għandhom it- tendenza li jieħdu infezzjonijiet ta 'spiss. jistgħu jintużaw ukoll f' pazjenti li jeħtieġu antikorpi addizzjonali għall- fejqan ta' ċertu mard infjammatorju (mard awtoimmuni).

this includes rheumatoid arthritis and off-label autoimmune diseases, including systemic lupus erythematosus (sle) and vasculitis.
dan jinkludi artrite rewmatika u mard awtoimmuni off-label ieħor, inkluż lupus eritematosus sistemika (sle) u vaskulite.

inform your healthcare professional if you have a history of autoimmune disease.
informa lill-professjonist tal-kura ta’ saħħtek jekk għandek storja mgħoddija ta’ mard awtoimmuni.

these autoimmune diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, sjögren's syndrome and dermatomyositis/ polymyositis.
dan il- mard awtoimmuni jinkludi artrite rewmatojde, lupus erythematosus sistemiku, skleroderma, is- sindrome ta ’ sjögren jew dermatomijosite/ polimijosite.

for patients with a history of autoimmune disease, see also section 4.4.
għal pazjenti bi storja ta’ mard awtoimmuni, ara wkoll is-sezzjoni 4.4.

most of them are genetic diseases, the others being rare cancers, autoimmune diseases, congenital malformations, toxic and infectious diseases, among other categories.
Ħafna minnu huwa mard ġenetiku, bl-oħrajn ikunu kankri rari, mard awtoimmun, malformazzjonijiet konġenitali, mard tossiku u infettuż, fost kategoriji oħrajn.

autoimmune hepatitis; or history of autoimmune disease; immunosuppressed transplant recipients.
epatite awtoimmuni; jew passat mediku ta’ mard awtoimmuni; pazjenti immunosoppressi li rċivew trapjant

the safety and efficacy of the use of inductos in patients with known autoimmune disease have not been established.
is-sigurtà u l-effikaċja tal-użu ta’ inductos f’pazjenti li hu magħruf li għandhom mard awtoimmuni, ma kinux stabbiliti.